Other

Alexion Pharmaceuticals, Inc.

Enobia Pharma Inc.

Alexion Pharma Holding

Pierre Leonard

Philippe Crine

Guy Boileau

Thomas P Loisel

Isabelle Lemire

Robert Heft

Hal Landy

The present invention provides methods, compositions, and kits for the treatment of matrix mineralization disorders such as hypophosphatasia. In particular, the present invention provides polypeptides having a soluble alkaline phosphatase fused to an Fc domain of an immunoglobulin. Such polypeptides can be administered to patients, e.g., subcutaneously, to treat hypophosphatasia using enzyme replacement therapy. The invention also features nucleic acids encoding such polypeptides and the use of the nucleic acids for treating matrix mineralization disorders.

Methods, compositions, and kits for the treatment of matrix mineralization disorders

A tool to terminate, without back-reflection, the signal transmitted within singlemode optical fibers. The reflection-free termination is induced by exposing singlemode optical fibers to a series of macrobends at a predetermined extent. The macrobends are produced by straight or U-shape pins, pre or mechanically positioned, which are perpendicular to a base plate and supported by the base plate of the tool. The fibers are snaked manually through the pre-positioned pins or simply inserted in the U-shaped pins. The pre-positioned pins induce macrobends of a predetermined extent to the fiber/s which terminate, without back-reflection, the optical signal. Similarly, the mechanical design places the pins in position for inducing the macrobends of a predetermined extent and hence, terminating the optical signal without back-reflection.

Singlemode optical fiber signal termination tool

Growing community of inventors

Montreal, Canada

Pierre Leonard